Pregnancy-associated plasma protein A (PAPP-A): theoretical and clinical aspects
Authors:
- 1 June 2002
- journal article
- review article
- Published by Springer Nature in Bratislava Medical Journal
- Vol. 103 (6) , 194-205
Abstract
Pregnancy-associated plasma protein A (PAPP-A) is an important pregnancy protein. PAPP-A exists in pregnancy serum as a heterotetrameric 2:2 complex with the proform of eosinophil major basic protein (proMBP), forming an approximately 500 kDa and called PAPP-A/proMBP. The gene of PAPP-A has been assigned to human chromosome 9q 33.1. PAPP-A belongs to the metzincin superfamily of metalloproteinases. It contains five short consensus repeats (SCR) and three the lin-notch repeats (LNR) and in addition a putative Zn binding site. The main site of both PAPP-A and proMBP synthesis during pregnancy is the placenta as shown by in situ hybridization. PAPP-A seems to be the predominating IGFBP-4 proteinase in pregnancy serum. In the women the levels of PAPP-A are highest during pregnancy, when plasma levels increase by a factor of about 150 as compared to the nonpregnant state. PAPP-A is the most abundant in the peripheral maternal circulation. Determination of PAPP-A in pregnancy serum has a limited value in some complication in gravidity such as a threatened abortion, ectopic gravidity, preeclampsia or diabetes mellitus. PAPP-A determination will gain increasing importance since this protein seems to be the major biochemical marker of Down syndrome in the first trimester of pregnancy. Maternal serum levels of PAPP-A in the first trimester are significantly reduced when a fetus affected by Down syndrome is present. Low first trimester maternal serum levels were found not only in trisomy 21 but also in non-Down syndrome fetal aneuploidies. Another contribution of PAPP-A determination may be in differentation of stable and unstable angina pectoris. (Tab. 3, Fig. 5, Ref. 78.)Keywords
This publication has 60 references indexed in Scilit:
- First trimester PAPP‐A in the detection of non‐Down syndrome aneuploidyPrenatal Diagnosis, 2001
- Screening for trisomy 13 by fetal nuchal translucency and maternal serum free ?-hCG and PAPP-A at 10-14 weeks of gestationPrenatal Diagnosis, 2000
- Screening for trisomy 21 in twin pregnancies in the first trimester using free ?-hCG and PAPP-A, combined with fetal nuchal translucency thicknessPrenatal Diagnosis, 2000
- Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18Prenatal Diagnosis, 1999
- Second-trimester pregnancy associated plasma protein-A levels are reduced in Cornelia de Lange syndrome pregnanciesPrenatal Diagnosis, 1999
- Appropriate biochemical parameters in first-trimester screening for Down syndromePrenatal Diagnosis, 1999
- Maternal serum pregnancy-associated plasma protein A (PAPP-A) but not pregnancy-specific β1-glycoprotein (SP1) is a useful second-trimester marker for fetal trisomy 18Prenatal Diagnosis, 1999
- First trimester serum screening for down's syndromePrenatal Diagnosis, 1995
- Serum PAPP‐A and free β‐hCG are first‐trimester screening markers for down syndromePrenatal Diagnosis, 1994
- Pregnancy‐associated plasma protein A: A possible marker in the classification and prenatal diagnosis of Cornelia de Lange syndromePrenatal Diagnosis, 1983